Avient names Mike Frank CEO, Richard Fearon becomes non-executive chairman
Bitget2026/10/09 11:01Avient named Mike Frank president and CEO, effective immediately, replacing Ashish K. Khandpur, who moved to an advisory role through Dec. 31, 2026. Frank led UPL as CEO since 2022; earlier spent 25 years at Monsanto, most recently as global chief commercial officer. He also served as CEO of Nutrien Ag Solutions, leading a major transformation initiative. Lead independent director Richard H. Fearon became non-executive chairman of the board. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avient Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610090700PR_NEWS_USPR_____NY67662) on October 09, 2026, and is solely responsible for the information contained therein.
- Avient named Mike Frank president and CEO, effective immediately, replacing Ashish K. Khandpur, who moved to an advisory role through Dec. 31, 2026.
- Frank led UPL as CEO since 2022; earlier spent 25 years at Monsanto, most recently as global chief commercial officer.
- He also served as CEO of Nutrien Ag Solutions, leading a major transformation initiative.
- Lead independent director Richard H. Fearon became non-executive chairman of the board.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
JPMorgan raises AbbVie target price to $300